Showing results (341-350 of 782) with videos related to
Sort By:
Pageof 79
Expert Opinion on Therapeutic Targets|June 1, 2019
A preclinical overview of emerging therapeutic targets for glomerular diseasesPaola Cassis, Carlamaria Zoja, Luca Perico, et al.Microorganisms|January 13, 2019
Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic SyndromeSimona Buelli, Carlamaria Zoja, Giuseppe Remuzzi, et al.Pflugers Archiv : European Journal of Physiology|September 19, 2009
Angiotensin receptors as determinants of life spanPaola Cassis, Sara Conti, Giuseppe Remuzzi, et al.Expert Opinion on Emerging Drugs|November 8, 2014
Novel effective drugs for diabetic kidney disease? or not?Giorgio Gentile, Daniela Mastroluca, Piero Ruggenenti, et al.Scientific Reports|February 20, 2026
A scanning electron microscopy-based approach to explore subpodocyte space remodeling in diabetic kidneys of mice and humansSara Conti, Ariela Benigni, Giuseppe Remuzzi, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 30, 2026
Complement-Mediated Postpartum Atypical Hemolytic Uremic Syndrome With Collapsing Focal Segmental Glomerulosclerosis Associated With a Novel CFHR5 Copy Number VariantRossella Piras, Carolina Martinatto, Elena Bresin, et al.Journal of Nephrology|September 24, 2002
Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiencyRoberto Pisoni, Rita Faraone, Piero Ruggenent, et al.Trends in Molecular Medicine|February 21, 2025
Is there a place for engineered immune cell therapies in autoimmune diseases?Luca Perico, Federica Casiraghi, Ariela Benigni, et al.International Journal of Cardiology|September 15, 2010
Effects of high dose aleglitazar on renal function in patients with type 2 diabetesMatthias Herz, Flavio Gaspari, Norberto Perico, et al.Frontiers in Genetics|August 21, 2019
Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 DiabetesElisabetta Valoti, Marina Noris, Annalisa Perna, et al.Pageof 79